Literature DB >> 2076910

Pharmacokinetics of imipenem in patients undergoing major colon surgery.

M Erttmann1, R Krausse, U Ullmann.   

Abstract

Ten patients about to undergo a colorectal operation lasting an average of three hours received 500 mg each of imipenem and cilastatin i.v. preoperatively. During the operation blood and tissue samples were taken in order to determine the serum kinetics of the substances as well as the levels of imipenem in the cutis, subcutis, fascia, muscle, parietal peritoneum and colon. The imipenem concentrations were measured by HPLC. The mean peak serum concentration was 26 mg/l, the mean half-life 55 min and the AUC 40 mg/l/h-1. The serum pharmacokinetics of imipenem was subject to substantially larger fluctuations in this patient group than in subjects or patients without surgery. Imipenem rapidly penetrates into tissue, with peak concentrations being reached after 10-25 min. The highest imipenem concentrations were found in the colon, the lowest in the cutis and subcutis. After 1 h a level of 8 mg/kg imipenem was still found in the colon. The concentrations were greater than 1 mg/kg in all tissues for more than 3 h p. a. and thus within this period exceeded the MICs of Escherichia coli and Bacteroides fragilis, the indicator organisms of intraabdominal infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076910     DOI: 10.1007/BF01646409

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Determination of imipenem and cilastatin in serum and tissue by high-pressure liquid chromatography.

Authors:  R Krausse; U Ullmann
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

2.  Pharmacokinetics of imipenem-cilastatin in serum and tissue.

Authors:  A Kümmel; V Schlosser; E Petersen; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

3.  The binding of antibiotics to serum proteins.

Authors:  G N Rolinson; R Sutherland
Journal:  Br J Pharmacol Chemother       Date:  1965-12

Review 4.  [Pharmacokinetics and antimicrobial activity of imipenem].

Authors:  G A Dette; H Knothe
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 5.  The use of antibiotic serum levels to predict concentrations in tissues.

Authors:  D M Ryan; O Cars; B Hoffstedt
Journal:  Scand J Infect Dis       Date:  1986

Review 6.  An overview of the pharmacology of imipenem/cilastatin.

Authors:  G L Drusano
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

7.  Imipenem pharmacokinetics in elective colorectal surgery.

Authors:  P C Gartell; G L Sutton; I Eardley; M Porte; E A Taylor
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

8.  Imipenem/cilastatin: a multicentre international study of its clinical efficacy, safety and potential as empirical therapy.

Authors:  C Wang; F Pappas; T Cook
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

9.  [Dosage of imipenem/cilastatin].

Authors:  P M Shah
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 10.  Antibacterial activity of imipenem: the first thienamycin antibiotic.

Authors:  H Kropp; L Gerckens; J G Sundelof; F M Kahan
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug
View more
  2 in total

Review 1.  Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.

Authors:  P Benfield; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.